Amgen Blasts Calls for Same-Name Biosimilars

Generic Line
Hot on the heels of Amgen’s state-level campaign to limit dispensation of biosimilars, the biotech is voicing strong opposition to plans by the FDA to allow biosimilars to share the same international non-proprietary name (INN) as the biologic they reference, calling for unique INNs.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00